Gene Panel Global Market Report 2025

The gene panel market size has grown rapidly in recent years. It will grow from $2.14 billion in 2024 to $2.48 billion in 2025 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period was driven by the rising prevalence of hereditary disorders, the growing need for genetic screening, increasing research and development activities, the higher incidence of congenital diseases, and the expanding demand for advanced treatment options.

The gene panel market size is expected to see rapid growth in the next few years. It will grow to $4.37 billion in 2029 at a compound annual growth rate (CAGR) of 15.3%. The growth in the forecast period is expected to be driven by the rising incidence of chronic diseases and cancer, growing awareness of genetic testing, and increasing government initiatives and healthcare spending. Key trends include advancements in gene panel technology, strategic collaborations, the expansion of personalized treatment approaches, the integration of artificial intelligence, and the use of advanced bioinformatics tools.

The rising prevalence of cancer is expected to drive the growth of the gene panel market. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, which can invade and damage surrounding tissues and organs. Factors such as aging populations, lifestyle changes, environmental exposures, and advancements in detection and diagnostic technologies are contributing to the increasing number of cancer cases. Gene panels play a crucial role in cancer diagnosis by enabling comprehensive genetic testing to identify mutations and alterations in specific genes, facilitating personalized treatment strategies and improving patient outcomes. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that an estimated 9.7 million people died from cancer in 2022, with 20 million new cases recorded. Lung cancer was the most prevalent, accounting for 12.4% of all new cases, with 2.5 million diagnoses worldwide. This increasing cancer burden continues to drive demand for gene panel testing.

Leading companies in the gene panel market are focusing on developing advanced oncology panels to enhance the accuracy, efficiency, and comprehensiveness of cancer diagnostics and personalized treatment approaches. Oncology panels are specialized gene panels that analyze multiple genes associated with cancer, identifying genetic mutations and alterations to aid in diagnosis, prognosis, and treatment planning. For instance, in May 2023, Vizgen Inc., a US-based biotechnology company, introduced the MERFISH PanCancer Pathways Panel, providing a customizable option for scientists exploring spatial genomics. These predesigned panels are optimized for various research applications, including cancer studies, and offer enhanced error robustness for reliable and reproducible results. By integrating spatial information with gene expression data, the panels provide deeper insights into tumor microenvironments and cellular interactions, advancing targeted cancer research and therapeutic development. This innovation marks a significant breakthrough in spatial biology, allowing researchers to analyze complex biological systems with unprecedented detail.

In May 2022, Sema4, a US-based health intelligence company, acquired GeneDx in a $322 million transaction. This acquisition bolsters Sema4’s position as a leading provider of genomic testing in the U.S., enhancing its health information database to improve patient care and therapeutic development. GeneDx, also based in the U.S., specializes in comprehensive diagnostic services for rare genetic disorders, inherited diseases, and cancers, further strengthening Sema4’s capabilities in precision medicine.

Major players in the gene panel market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Intermountain Healthcare, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., OPKO Health Inc., Myriad Genetics Inc., Guardant Health Inc., Invitae Corp., Integrated DNA Technologies Inc., Bio-Rad Laboratories Inc., Novogene Corporation, Fulgent Genetics Inc., MedGenome Inc., OriGene Technologies Inc., Centogene AG, Blueprint Genetics Inc., BIONEER Corporation, BGI Group Ltd., Vizgen Inc., Primbio Research Institute LLC.

North America was the largest region in the gene panel market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gene panel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gene panel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gene panels are a set of specific genes selected for testing in a single assay to analyze genetic variations associated with particular diseases or conditions. They are utilized for diagnosing genetic disorders, detecting inherited diseases, and enabling personalized treatment plans by examining multiple genes simultaneously, particularly in cancer, rare diseases, and other genetic conditions.

The primary gene panel products and services include test kits and testing services. Test kits are pre-packaged tools containing all necessary reagents and instructions for genetic analysis. These panels employ various technologies, such as amplicon-based and hybridization-based methods, and can be either predesigned or customized. They are applied in cancer risk assessment, congenital disease diagnosis, pharmacogenetics, and other areas, serving end users such as research institutes, hospitals, diagnostic centers, pharmaceutical companies, and others.

The gene panel market research report is one of a series of new reports that provides gene panel market statistics, including gene panel industry global market size, regional shares, competitors with a gene panel market share, detailed gene panel market segments, market trends and opportunities, and any further data you may need to thrive in the gene panel industry. This gene panel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gene panel market consists of revenues earned by entities by providing services such as custom panel design, next-generation sequencing, bioinformatics analysis, clinical interpretation, and pharmacogenomics services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene panel market also includes sales of metabolic disorder panels, reproductive health panels, carrier screening panels, and neurological disorder panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.